<img alt="" src="https://secure.intelligentdataintuition.com/780345.png" style="display:none;">

Hear directly from patients assessed for cognitive concerns using Linus Health. Explore their stories.

Nov 16, 2026

Linus Health to Present Six Studies at CTAD 2026 on Detection of Cognitive Impairment, Amyloid Prediction, and Patient-Centered Outcomes

BOSTON, Nov. 16, 2026 -- Linus Health, an AI-driven brain health company focused on early detection and proactive intervention, will present six scientific posters at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place today through Nov. 19 in Boston. The studies evaluate Linus Health’s AI-enabled digital cognitive assessments, its Radar™ dementia risk model, and its electronic Person-Specific Outcome Measure (ePSOM). The findings support the use of the company’s technologies to help clinicians and trial sponsors identify earlier the individuals who may benefit from further evaluation for Alzheimer’s disease trials or therapies, and measure the benefits that matter most to patients.

Two of the posters focus on Linus Cognitive Assess, formerly the Digital Clock and Recall (DCR™), a brief tablet-based assessment that pairs the DCTclock™ digital clock-drawing test with word recall. Two more examine Linus Cognitive Profile, formerly the Digital Assessment of Cognition (DAC), a seven-minute speech-based assessment of memory, working memory, and category fluency, including its ability to predict amyloid status on positron emission tomography (PET). The remaining posters report on the ePSOM in Japan and on an updated version of Radar, which estimates dementia risk from claims data.

The research arrives as an estimated 7.4 million Americans age 65 and older are living with Alzheimer’s dementia, according to the Alzheimer’s Association’s 2026 Facts and Figures report. As new disease-modifying therapies reach more patients, clinical trials are also enrolling participants earlier in the disease. Both shifts require tools that quickly and accurately identify eligible individuals, along with measures that help assess whether treatment effects are meaningful to patients in their daily lives.

“Alzheimer’s research and routine clinical care increasingly depend on the same foundation of identifying cognitive change early and acting on it with confidence,” said David Bates, PhD, CEO and Co-Founder of Linus Health. “Many health systems are building brain health programs to prepare for more patients who may qualify for new therapies, while drug developers need faster enrollment of more representative trial populations. CTAD brings both communities together and is a natural place to share the evidence behind validated digital tools that can scale from a local health system to a global clinical trial.”

The amyloid PET and Radar posters will be on display from 2 p.m. today through 5:30 p.m. tomorrow, and the other four on Thursday, Nov. 19, from 7:15 a.m. to 5 p.m. (all Eastern Time).

Titles and highlights from the poster presentations include:

P429: “Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment”

Drawing on six research cohorts and 27,033 real-world assessments from health system customers, the study found that Linus Cognitive Assess demonstrates strong technical validity, reliability, and usability, with a 93% completion rate and a median completion time of 4.12 minutes (including instructions) in an 8,270-patient subset with complete workflow logs. Its AI-derived Cognition Score also improved detection of cognitive impairment compared with the original score in a research cohort, supporting its use in primary care and clinical trial enrichment.

P428: “A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care”

Researchers analyzed data from 814 participants in Bio-Hermes-001, a clinical study that enrolled volunteers across stages of cognitive health, including 125 diagnosed with mild dementia. Using Linus Cognitive Assess as the first step identified 90% of those dementia cases, compared with 70% for the widely used Mini-Cog alone, while also producing fewer false positives. Running the Mini-Cog first and referring only those who scored positive to Linus Cognitive Assess identified 66% of cases—fewer than the Mini-Cog alone—because this pathway excludes patients the Mini-Cog missed and requires a positive second assessment. The findings suggest potential to improve dementia detection in primary care, though confirmation in clinical practice is needed.

P090: “Predicting Amyloid PET Positivity from a Brief Digital Cognitive Assessment in Memory Clinic Patients”

In a retrospective study of 90 memory clinic patients undergoing evaluation for anti-amyloid therapy, delayed memory measures from the Linus Cognitive Profile distinguished amyloid PET-positive from PET-negative patients with an area under the curve (AUC) of 0.81. These preliminary findings support further prospective evaluation as a triage tool before biomarker testing.

P449: “Understanding Cognitive Impairment Through Analysis of Process Metrics Derived from the Digital Assessment of Cognition”

In a study of 283 memory clinic patients, adding automatically derived cognitive and speech process metrics from the Linus Cognitive Profile, such as response timing, word length, and errors, to an age-only model raised balanced accuracy in classifying patients as cognitively unimpaired, with mild cognitive impairment (MCI), or with probable dementia from 38.4% to 65.2%.

P409: “Measuring Meaningful Benefits Across Cultures in AD Trials: Feasibility, Applicability, and User Acceptability of the ePSOM Tool in Japanese Memory Clinics”

At two Japanese memory clinics, all 50 participants with MCI or early dementia due to Alzheimer’s disease completed the ePSOM (92% with assistance), and 80% found its domains relevant to their lives, indicating that the tool is feasible, acceptable, and able to capture personally meaningful priorities in a culturally distinct setting. The study did not assess responsiveness to treatment or treatment benefit.

P122: “Improved Performance and Fairness of Dementia Risk Stratification from Claims Data with Machine Learning”

Across a 5% sample of Medicare claims from 2019 to 2024, an updated Radar model built with machine learning better distinguished Medicare beneficiaries aged 65 and older with and without a newly recorded dementia diagnosis over the following year than published algorithms (AUC of 0.831 vs. 0.757 for eRADAR and 0.801 for RADAR-CMS) and more consistently across age groups, supporting its use for population health management and clinical trial recruitment.

“This is the third consecutive year Linus Health scientists have presented multiple studies at CTAD,” said Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health. “Our technologies are supported by more than 160 peer-reviewed papers, and we share new findings each year at leading international meetings, including the Alzheimer’s Association International Conference (AAIC) and the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD). Clinicians and trial sponsors need to see a digital assessment demonstrate validity, reliability, and clinical utility through rigorous research before they rely on it, and we intend to keep holding our work to that standard.”

Alongside the poster presentations, Linus Health scientists will be available throughout the conference to meet and discuss the use of the company’s digital assessments to support trial recruitment, strengthen outcome measures, and generate real-world evidence in Alzheimer’s research. Click here to schedule a meeting with Linus Health at CTAD 2026.

About Linus Health

Linus Health is a Boston-based digital health company focused on improving brain health around the world. The company develops science-driven digital assessments and AI-enabled analytics that help clinicians and researchers identify cognitive change earlier, guide next steps in care, and support more proactive, personalized intervention. Linus Health works with healthcare delivery organizations, research institutions, and life sciences partners to advance earlier detection and better brain health outcomes. To learn more, visit www.linushealth.com or follow Linus Health on LinkedIn.

Media Contact

Supreme Communications for Linus Health
LinusHealthPR@supremecomms.ai